Drug Pricing

Pharmalot Ed Silverman

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

Biotech Matthew Herper

For its first two medicines, EQRx abandons its bold strategy to lower drug prices

Politics STAT Staff

Health and science are on the ballot this election. Here’s what we’re watching

Pharmalot Ed Silverman

Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages

Politics Rachel Cohrs

Drugmakers will be penalized if they hike prices on patients in private insurance market

Exclusive Rachel Cohrs

Medicare tasks a senior adviser with staffing its new drug pricing division

Exclusive Rachel Cohrs

Medicare lays out the bureaucracy it will need to negotiate drug prices

Exclusive Rachel Cohrs

Democrats concede to clean user fee agreement to fund FDA

Exclusive Rachel Cohrs

White House pitches drug pricing reforms as a way to extend cancer patients’ lives

Pharmalot Ed Silverman

Inflation caused another big drop in net drug prices, analysis finds

First Opinion Jeff Baldetti

Market share isn’t the only metric for biosimilars’ success

Politics Rachel Cohrs

Patients for Affordable Drugs taps new leader

Pharmalot Ed Silverman

Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

Pharmalot Ed Silverman

Swiss authorities raid Novartis offices seeking info on patents used to block rivals

Pharmalot Ed Silverman

J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review

First Opinion Steve Pearson

Launch prices: tackling the next drug pricing challenge

Pharmalot Ed Silverman

Pharma donations to patient charities may violate the ‘spirit’ of anti-kickback laws

Pharmalot Ed Silverman

Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business

First Opinion Utibe R. Essien

The Inflation Reduction Act: One step closer to pharmacoequity?

Pharmalot Ed Silverman

Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada

Politics Rachel Cohrs

Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use

Pharmalot Ed Silverman

Cepheid faces fresh criticism over the pricing of its TB diagnostics

Pharmalot Ed Silverman

Sales from controversial drug discount program rose to $44 billion last year

Politics Rachel Cohrs

Cancer patient who devoted six years to drug pricing reform isn’t done yet

Politics Rachel Cohrs

drug pricing

Most Read

After 30 years of 340B, it’s time for data and an honest conversation

Merck fined $39 million by Spain’s antitrust regulator for ‘serious’ violation

How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’

How states can act to limit drug price increases, saving employers and workers billions

With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn’t been the biggest problem

Unpacking the drug pricing policies that Congress just approved

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need

All Coverage

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

For its first two medicines, EQRx abandons its bold strategy to lower drug prices

Health and science are on the ballot this election. Here’s what we’re watching

Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages

Drugmakers will be penalized if they hike prices on patients in private insurance market

Medicare tasks a senior adviser with staffing its new drug pricing division

Medicare lays out the bureaucracy it will need to negotiate drug prices

Democrats concede to clean user fee agreement to fund FDA

White House pitches drug pricing reforms as a way to extend cancer patients’ lives

Inflation caused another big drop in net drug prices, analysis finds

Market share isn’t the only metric for biosimilars’ success

Patients for Affordable Drugs taps new leader

Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug

Swiss authorities raid Novartis offices seeking info on patents used to block rivals

J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review

Launch prices: tackling the next drug pricing challenge

Pharma donations to patient charities may violate the ‘spirit’ of anti-kickback laws

Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business

The Inflation Reduction Act: One step closer to pharmacoequity?

Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada

Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use

Cepheid faces fresh criticism over the pricing of its TB diagnostics

Sales from controversial drug discount program rose to $44 billion last year

Cancer patient who devoted six years to drug pricing reform isn’t done yet

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day